Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.

Authors

• Paolo Antonio Ascierto, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
• Bernard Fox, Providence Cancer Center, Portland, OR, United States
• Walter Urba, Providence Cancer Center, Portland, OR, United States
• Ana Carrizosa Anderson, Department of Neurology, Harvard Medical School, Boston, MA, United States
• Michael B Atkins, Oncology Georgetown University, Washington, DC, United States
• Ernest C Borden, Comprehensive Cancer Center, University of Wisconsin System, Madison, WI, United States
• Julie Brahmer, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
• Lisa H Butterfield, Research Parker Institute for Cancer Immunotherapy, San Francisco, CA, United States; Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, United States
• Alessandra Cesano, ESSA Pharma Inc, Redwood City, CA, United States
• Daniel Chen, IGM Biosciences Inc, Mountain View, CA, United States
• Tanja de Gruijl, Medical Oncology - Cancer Center Amsterdam, Amsterdam UMC, Locatie VUMC, Amsterdam, Netherlands
• Robert O Dillman, AIVITA Biomedical Inc, Irvine, CA, United States
• Charles G Drake, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, United States
• Leisha A Emens, Medicine, UPMC Hillman Cancer Center, Pittsburgh, United States
• Thomas F Gajewski, Pathology and Medicine, University of Chicago, Chicago, IL, United States
• James L Gulley, NCI, National Institutes of Health, Bethesda, MD, United States
• F Stephen Hodi, Dana Farber Cancer Institute, Boston, MA, United States
• Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX, United States
• David Kaufman, Bill and Melinda Gates Medical Research Institute, Cambridge, MA, United States
• Howard Kaufman, Surgery Immuneering Corp New York, New York, NY, United States
• Michael Lotze, University of Pittsburgh Medical Center, Pittsburgh, PA, United States
• Douglas G McNeel, Medicine University of Wisconsin Madison, Madison, WI, United States
• Kim Margolin, Medical Oncology, City of Hope National Medical Center, Duarte, CA, United States
• Francesco Marincola, Refuge Biotechnologies, Menlo Park, CA, United States
• Michael J Mastrangelo, Thomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, PA, United StatesFollow
• Marcela V Maus, Massachusetts General Hospital Cancer Center, Harvard Medical Schoo, Massachusetts General Hospital, Boston, MA, United States
• David R Parkinson, ESSA Pharma Inc, Palo Alto, CA, United States
• Pedro J Romero, Oncology University of Lausanne, Epalinges, VD, Switzerland
• Paul M Sondel, Pediatrics University of Wisconsin Madison, Madison, WI, United States
• Stefani Spranger, Massachusetts Institute of Technology Koch, Institute for Integrative Cancer Research, Cambridge, MA, United States
• Mario Sznol, Yale Cancer Center, Yale School of Medicine, New Haven, CT, United States
• George J Weiner, Interdisciplinary Program in Immunology, University of Iowa, Iowa City, IA, United States; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States; Department of Internal Medicine, Division of General Medicine, University of Iowa, Iowa City, IA, United States
• Jon M Wiggington, MacroGenics Inc, Rockville, MD, United States
• Jeffrey S Weber, Laura and Isaac Perlmutter Comprehensive Cancer Center, NYU Langone Medical Center, New York, NY, United States

Document Type

Article

Publication Date

4-16-2020

Comments

This article has been peer reviewed. It was published in: Journal for ImmunoTherapy of Cancer.

Volume 8, Issue 1, 16 April 2020 (original published article metadata).

The published (corrected) version is available at DOI: 10.1136/jitc-2020-000878corr1 (Published online 2020 Apr 28)

Copyright © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Recommended Citation

Ascierto, Paolo Antonio; Fox, Bernard; Urba, Walter; Anderson, Ana Carrizosa; Atkins, Michael B; Borden, Ernest C; Brahmer, Julie; Butterfield, Lisa H; Cesano, Alessandra; Chen, Daniel; de Gruijl, Tanja; Dillman, Robert O; Drake, Charles G; Emens, Leisha A; Gajewski, Thomas F; Gulley, James L; Stephen Hodi, F; Hwu, Patrick; Kaufman, David; Kaufman, Howard; Lotze, Michael; McNeel, Douglas G; Margolin, Kim; Marincola, Francesco; Mastrangelo, Michael J; Maus, Marcela V; Parkinson, David R; Romero, Pedro J; Sondel, Paul M; Spranger, Stefani; Sznol, Mario; Weiner, George J; Wiggington, Jon M; and Weber, Jeffrey S, "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19." (2020). Department of Microbiology and Immunology Faculty Papers. Paper 117.
https://jdc.jefferson.edu/mifp/117

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

32300051